IL327381A - טיפול לטיפול בסוכרת סוג 1 באמצעות מעכבי rock2 וdyrk1- - Google Patents
טיפול לטיפול בסוכרת סוג 1 באמצעות מעכבי rock2 וdyrk1-Info
- Publication number
- IL327381A IL327381A IL327381A IL32738126A IL327381A IL 327381 A IL327381 A IL 327381A IL 327381 A IL327381 A IL 327381A IL 32738126 A IL32738126 A IL 32738126A IL 327381 A IL327381 A IL 327381A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- group
- 11aro
- 21ar11arn
- cycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363586192P | 2023-09-28 | 2023-09-28 | |
| PCT/IB2024/059567 WO2025069008A1 (en) | 2023-09-28 | 2024-09-30 | Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL327381A true IL327381A (he) | 2026-05-01 |
Family
ID=93257597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL327381A IL327381A (he) | 2023-09-28 | 2024-09-30 | טיפול לטיפול בסוכרת סוג 1 באמצעות מעכבי rock2 וdyrk1- |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4784127A1 (he) |
| KR (1) | KR20260099122A (he) |
| CN (1) | CN122341372A (he) |
| AU (1) | AU2024352423A1 (he) |
| IL (1) | IL327381A (he) |
| WO (1) | WO2025069008A1 (he) |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005723A1 (fr) | 1988-11-24 | 1990-05-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine |
| US7410975B2 (en) | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
| US7547779B2 (en) | 2003-10-06 | 2009-06-16 | Glaxo Group Limited | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors |
| JP4857128B2 (ja) | 2004-02-20 | 2012-01-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規な化合物 |
| DE102004017438A1 (de) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
| CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| PT1905452E (pt) | 2005-07-12 | 2013-07-16 | Kowa Co | Agente para a prevenção ou tratamento do glaucoma |
| US20110021776A1 (en) | 2006-08-28 | 2011-01-27 | Medipropharma, Inc. | Compositions for the treatment of central nervous system diseases and disorders |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB0705566D0 (en) | 2007-03-23 | 2007-05-02 | Univ Dundee | Method of treating learning impairment in down's syndrome subjects |
| FR2919608B1 (fr) | 2007-08-01 | 2012-10-05 | Univ Rennes | Derives d'imidazolones,procede de preparation et applications biologiques |
| KR20100010894A (ko) | 2008-07-23 | 2010-02-02 | 가부시키가이샤 키노파마 | Dyrk를 저해하는 화합물을 함유하는 의약 조성물 |
| EP2266562A1 (en) | 2009-06-23 | 2010-12-29 | Centre National de la Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
| AU2010298440B2 (en) | 2009-09-22 | 2016-05-19 | Neuronascent, Inc | Methods and pharmaceutical compositions for treating down syndrome |
| WO2011041655A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Quinazolin-4-amine derivatives; and methods of use |
| US9221808B2 (en) | 2010-04-16 | 2015-12-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use |
| JP5565705B2 (ja) | 2011-01-17 | 2014-08-06 | Jx日鉱日石エネルギー株式会社 | 脱硫器 |
| US20120184542A1 (en) | 2011-01-19 | 2012-07-19 | Kevin Anderson | Pyrido pyrimidines |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| US20120184548A1 (en) | 2011-01-19 | 2012-07-19 | Romyr Dominique | Carboxylic acid aryl amides |
| KR102006749B1 (ko) | 2011-08-19 | 2019-08-02 | 디악쏘니 | Dyrk1 억제제 및 이의 용도 |
| RS63503B1 (sr) | 2012-10-05 | 2022-09-30 | Kadmon Corporation Llc | Inhibitori rho kinaze |
| US11311541B2 (en) | 2014-04-09 | 2022-04-26 | Kadmon Corporation, Llc | Treatment of GVHD |
| PL3558321T3 (pl) | 2016-12-23 | 2023-10-23 | Felicitex Therapeutics, Inc. | Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b |
| WO2019000683A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| US10329282B2 (en) | 2017-06-30 | 2019-06-25 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
| JP7311228B2 (ja) | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
| CN112969694B (zh) | 2018-11-09 | 2023-06-13 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途 |
| CN113490493B (zh) | 2019-03-01 | 2024-10-29 | 北京泰德制药股份有限公司 | 治疗脂肪性肝病和/或脂肪性肝炎的方法 |
| TWI804743B (zh) | 2019-06-25 | 2023-06-11 | 大陸商北京泰德製藥股份有限公司 | 治療特發性肺纖維化的方法 |
| WO2021064141A1 (en) | 2019-10-02 | 2021-04-08 | Tolremo Therapeutics Ag | Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b |
| US20230303534A1 (en) | 2020-08-31 | 2023-09-28 | Beijing Tide Pharmaceutical Co., Ltd. | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method |
| CN118772118A (zh) | 2020-08-31 | 2024-10-15 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途 |
| AU2022341315A1 (en) * | 2021-09-13 | 2024-05-02 | Provention Bio, Inc. | Methods and compositions comprising anti-cd3 antibodies and dyrk1a inhibitors for treating diabetes |
| CA3231781A1 (en) * | 2021-09-18 | 2023-03-23 | Beijing Tide Pharmaceutical Co., Ltd. | Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof |
| US20250289807A1 (en) | 2022-04-29 | 2025-09-18 | Graviton Bioscience Bv | Inhibitors of ROCK2 |
| EP4622973A1 (en) | 2022-11-21 | 2025-10-01 | Graviton Bioscience BV | Inhibitors of rock2 |
| CN116355832A (zh) * | 2023-03-24 | 2023-06-30 | 四川大学华西医院 | 尿液上皮样细胞来源的iPSCs诱导分化制备人胰腺β细胞的方法和用途 |
-
2024
- 2024-09-30 IL IL327381A patent/IL327381A/he unknown
- 2024-09-30 EP EP24794927.4A patent/EP4784127A1/en active Pending
- 2024-09-30 KR KR1020267013470A patent/KR20260099122A/ko active Pending
- 2024-09-30 CN CN202480074308.2A patent/CN122341372A/zh active Pending
- 2024-09-30 WO PCT/IB2024/059567 patent/WO2025069008A1/en not_active Ceased
- 2024-09-30 AU AU2024352423A patent/AU2024352423A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20260099122A (ko) | 2026-06-26 |
| AU2024352423A1 (en) | 2026-05-14 |
| EP4784127A1 (en) | 2026-08-05 |
| WO2025069008A1 (en) | 2025-04-03 |
| CN122341372A (zh) | 2026-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000271A (es) | Inhibidor de shp2 y uso del mismo. | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| NZ515567A (en) | Method for treating chronic pain using MEK inhibitors | |
| TW200505439A (en) | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight loss agents | |
| CY1107484T1 (el) | Παραγωγα γκελνταναμυκινης χρησιμοποιουμενα για τη θεραπεια καρκινου | |
| NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
| MX2009012197A (es) | Metodos para tratamiento de ulceras en la piel. | |
| TW200507833A (en) | Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents | |
| PH12022553501A1 (en) | Alk2 inhibitors for the treatment of anemia | |
| GB202003059D0 (en) | Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain | |
| MX2023011633A (es) | Inhibidores de sos1 e inhibidores de ras para su uso en el tratamiento del dolor. | |
| MA69153A1 (fr) | Méthodes de traitement d'une splénomégalie | |
| MX2022007113A (es) | Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas. | |
| IL308152A (he) | 2-פלואורואלקיל-4,3,1-אוקסאדיאזול-5-איל-תיאזול, מעכבי hdac6 לשימוש בטיפול במחלה מטבולית ו hfpef | |
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| EP4157241A4 (en) | AGENTS AND METHODS FOR THE TREATMENT OF TAUOPATHIES | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| EP4445914A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE | |
| MX2024015040A (es) | Fitusiran para el tratamiento de la hemofilia a y b en pacientes pediatricos | |
| DE60309887D1 (de) | Kombination von einem aromatasehemmer mit einem bisphosphonat | |
| WO2023196584A3 (en) | Endocytosis inhibitors and their use for pain treatment | |
| CA3305368A1 (en) | Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors | |
| MX2021002590A (es) | Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor. | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
| IL327385A (he) | מעכבי rock2 בטיפול בהשמנה |